Chanchung Biotechnology

Changchun BCHT Biotechnology is a leading Chinese biopharmaceutical company specializing in the research, development, production, and commercialization of vaccines. The company is a major provider of the live varicella vaccine in China and has successfully launched an innovative nasal spray influenza vaccine in collaboration with the World Health Organization. BCHT also produces a human rabies vaccine and recently introduced the first domestically developed live herpes zoster vaccine to the Chinese market. Headquartered in Changchun, the company is listed on the Shanghai Stock Exchange and continues to expand its pipeline into recombinant vaccines and monoclonal antibodies.